Patients Under Gastroesophageal Reflux Disease Drugs Need To Manage Their Body Weight
GERD is the most common esophageal disorder and frequently encountered in the primary care setting.
Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment.
However, the possible impact of changes in body weight (BW) or body mass index (BMI) in reflux patients while on long-term PPI therapy has not been examined.
During the study, 52 patients with GERD were treated with PPI for a mean of 2.2 years and also advised on lifestyle modifications (e.g. selective diet, weight management).
The researchers found that there was no difference in BW and BMI between reflux patients and controls at baseline.
Patients with GERD showed increases in BW, but no such changes were noted in the control group. Mean BW increased by 3.5 kg in 37 reflux patients but decreased in only 6 patients during treatment.
They concluded that reflux patients treated with a daily maintenance therapy of PPI should be strongly encouraged to manage their body weight through lifestyle modifications such as proper diet and avoidance of overeating.
The study is published in the World Journal of Gastroenterology.